Comparison of mucosal vs. intravenous infectious dose of a cell associated SIV32H challenge stock in rhesus macaques.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Comparison of mucosal vs. intravenous infectious dose of a cell associated SIV32H challenge stock in rhesus macaques.

Symp Nonhum Primate Models AIDS. 1991 Nov 6-9;9:127 (abstract no. 109). Unique Identifier : AIDSLINE PRIM9/1740292
Niphuis H; Cranage M; Baskerville A; ten Haaft P; Koornstra W; Dubbes R; Heeney JL; Dept. of Chronic and Infectious Diseases, ITRI-TNO, Rijswijk, The; Netherlands.

Abstract: A rhesus macaque infected with 10 monkey infectious doses (MID50) of the 11-88 stock of SIV32H served as a single source of peripheral blood mononuclear cells (PBMCs) and plasma taken at a single time point to establish a cell associated virus stock for homologous or heterologous vaccine challenge. At the time of collection the monkey showed early signs of disease, a mild plasma antigenemia and a decrease in CD4+/CD29- lymphocytes. PBMCs were found to be more than 90% viable (5 x 10(5) cells/ampule), following freezing and were analysed by FACScan for specific subset. Animals were infected either intravenously (i.v.) or via rectal mucosa with decreasing serial five-fold dilutions beginning at 1 x 10(6) lymphocytes per macaque. Mucosal challenge was controlled by administration of a previously determined cell-free dose of the 11-88 SIV32H. An MID was established by an endpoint dilution as determined by animals which remained sero-negative for SIV as determined by ELISA, virus isolation and PCR three months post-infection. The characteristics of this challenge stock and the minimum infectious dose via mucosal or i.v. route will be presented.

Keywords: Animal Antibodies, Viral/ANALYSIS Antigens, CD/ANALYSIS Antigens, Viral/ANALYSIS Comparative Study CD4-Positive T-Lymphocytes Enzyme-Linked Immunosorbent Assay Flow Cytometry Macaca mulatta Polymerase Chain Reaction SIV/IMMUNOLOGY/*PATHOGENICITY Viral Vaccines/ADMINISTRATION & DOSAGE ABSTRACT
920830
M9280909

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .